Literature DB >> 7561190

IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies.

S T Ishizaka1, P Piacente, J Silva, E M Mishkin.   

Abstract

IgG subclasses differ in their effector functions in a variety of in vitro assays. To assess the effect of antibody subclass differences on in vivo protective efficacy against herpes simplex virus (HSV), a series of subclass switch mutants was made from an anti-HSV glycoprotein D monoclonal antibody. Purified antibody was examined for the ability to protect against HSV-2 challenge in mice. IgG2a was found to be more effective than IgG1. This correlated both with activity in antibody-dependent cell-mediated cytotoxicity and with efficiency of complement-mediated neutralization. These data suggest that optimization of passive immunization against HSV requires consideration of antibody subclass.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561190     DOI: 10.1093/infdis/172.4.1108

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2.

Authors:  E L Parr; M B Parr
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

2.  DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.

Authors:  Sachin Gupta; Emily S Clark; James M Termini; Justin Boucher; Saravana Kanagavelu; Celia C LeBranche; Sakhi Abraham; David C Montefiori; Wasif N Khan; Geoffrey W Stone
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

3.  Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2.

Authors:  E L Parr; M B Parr
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

4.  Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants.

Authors:  Dominique Markine-Goriaynoff; Jean-Paul Coutelier
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1.

Authors:  S Sasaki; J Fukushima; K Hamajima; N Ishii; T Tsuji; K Q Xin; H Mohri; K Okuda
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

6.  Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.

Authors:  Staffan Görander; Ali M Harandi; Madelene Lindqvist; Tomas Bergström; Jan-Åke Liljeqvist
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

7.  Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1.

Authors:  S Sasaki; T Tsuji; K Hamajima; J Fukushima; N Ishii; T Kaneko; K Q Xin; H Mohri; I Aoki; T Okubo; K Nishioka; K Okuda
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

8.  Effects of the route of infection on immunoglobulin G subclasses and specificity of the reovirus-specific humoral immune response.

Authors:  A S Major; C F Cuff
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

9.  An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.

Authors:  Mojca Skoberne; Rhonda Cardin; Alexander Lee; Ana Kazimirova; Veronica Zielinski; Danielle Garvie; Amy Lundberg; Shane Larson; Fernando J Bravo; David I Bernstein; Jessica B Flechtner; Deborah Long
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

10.  Antibody limits in vivo murid herpesvirus-4 replication by IgG Fc receptor-dependent functions.

Authors:  Debbie E Wright; Susanna Colaco; Camilo Colaco; Philip G Stevenson
Journal:  J Gen Virol       Date:  2009-07-22       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.